News and Media
News and Media
High-Grade Glioma Relapse in Children: Onxeo announces the enrollment of the first patient in the phase 1b/2 clinical study conducted by the European ITCC consortium and sponsored by Institut Curie
September 1, 2022
Onxeo announces that Nasdaq approved the delisting of its shares from the First North Growth market in Copenhagen
August 30, 2022
Combined General Meeting of August 17, 2022: Onxeo shareholders approve withdrawal from the Nasdaq First North market in Copenhagen
August 17, 2022
Combined General Meeting of August 17, 2022: availability of preparatory documents and participation & voting procedures
July 29, 2022
Onxeo announces a Combined General Meeting on August 17, 2022
July 12, 2022
Initial IND application for AsiDNA Granted “Study May Proceed” by the U.S. FDA
June 30, 2022
Onxeo: Proceedings of the Combined Shareholders’ Meeting of June 15, 2022
June 16, 2022
Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer
April 7, 2022
Onxeo Reports its Full-Year 2021 Financial Results and announces additional financing of €12 million
April 6, 2022
Onxeo to present new preclinical data highlighting AsiDNA™’s ability to fight tumor resistance and protect from anticancer treatment toxicity at AACR Annual Meeting 2022
March 31, 2022
Onxeo’s new preclinical data confirm the relevance of combining AsiDNA™ with PARP inhibitors in treating homologous recombination proficient tumors
March 9, 2022
Onxeo Announces its Financial Agenda for 2022
January 13, 2022
Onxeo appoints Julien Miara as new interim CEO
January 3, 2022
Onxeo Continues to Strengthen its Board of Directors
November 23, 2021
New preclinical data confirm the ability of AsiDNA™ to tackle the drug-tolerant persister cells and prevent tumor resistance in several combination treatments
August 12, 2021
[wd_hustle id=”2″ type=”embedded”/]
